The trusted innovative sustained-release preparation JMX-2005 injection has been approved for clinical use.

On December 18th, Jumian trustworthy group announced that the company's 2.2 and 2.4 class new drug JMX-2005 injection has been approved by the National Medical Products Administration to conduct clinical trials. This drug is intended to improve ischemic symptoms such as rest pain and ulcers caused by peripheral artery disease.